Joint Partnership Announcement

J. Molner and Juno Pharmaceuticals Canada Announce joint partnership and licensing Agreement for Generic Injectable Drugs in Canada.

J. Molner, an Estonia-based pharmaceutical company specializing in the development of innovative generic drugs, and Juno Pharmaceuticals Canada, a Canadian specialty pharmaceutical company, announce a licensing agreement to commercialize two generic injectable drug products pending approval with Health Canada, and two generic injectable drug products under development at the J. Molner laboratory in Tallinn.

"We are pleased to partner with Juno Pharmaceuticals to bring our innovative generic injectable drugs to market in Canada," said Jason Grenfell-Gardner, CEO of J. Molner AS. "This agreement represents an important milestone for Molner, as it validates the strength of our product portfolio and our commitment to bringing affordable generic drugs to patients. We look forward to working closely with Juno to ensure the success of our products in Canada."

The licensed products are currently under review with Health Canada, and Molner anticipates approval of the first product later this year. Molner expects to receive additional regulatory approvals in Canada in the near future. The products will be supplied by Molner using contract manufacturers, while Juno will be responsible for the commercialization of the products in Canada.

"We are excited to partner with Molner to commercialize these important generic drugs in Canada," said Mark Mantel, CEO of Juno Pharmaceuticals. "Molner's innovative product portfolio and expertise in developing generic drugs make them an ideal partner for us. We look forward to working closely with Molner to ensure the success of these products in Canada.".

 

.